Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7908281 | 0.86 | HSP90AA1 (0.44) | HSP90AA1TSHRALDH1A1L3MBTL1PDCD1 | |
| SCHEMBL8835724 | 0.85 | CA12 (0.36) | HSP90AA1TSHRALDH1A1L3MBTL1PDCD1 | |
| SCHEMBL11162398 | 0.81 | HSP90AA1 (0.45) | HSP90AA1ALDH1A1HCAR2LMNAKMT2A | |
| SCHEMBL12305771 | 0.79 | HSP90AA1 (0.50) | HSP90AA1TSHRALDH1A1HCAR2SMN1; SMN2 | |
| SCHEMBL9094 | 0.79 | HSP90AA1 (0.50) | HSP90AA1TSHRALDH1A1HCAR2SMN1; SMN2 | |
| SCHEMBL12305754 | 0.79 | HSP90AA1 (0.50) | HSP90AA1TSHRALDH1A1HCAR2SMN1; SMN2 | |
| SCHEMBL2597946 | 0.78 | ALDH1A1 (0.49) | HSP90AA1TSHRALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL7368845 | 0.77 | POLB (0.43) | HSP90AA1TSHRALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL1508 | 0.77 | HSP90AA1 (0.55) | HSP90AA1TSHRALDH1A1L3MBTL1NPC1 | |
| SCHEMBL13908046 | 0.76 | HSP90AA1 (0.47) | HSP90AA1TSHRALDH1A1SMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| CN-117561240-A | Inhibitors of transglutaminase | 策迪拉有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-04 | — | — | US | disclosed |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3590928-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-09 | — | — | EP | disclosed |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-04-18 | — | — | US | disclosed |
| EP-2669279-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-2653468-A1 | Bicyclic Compound and Use Thereof for Medical Purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-2460801-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2086993-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | Zedira GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| CN-1057995-C | Substituted ortho-ethenylphenylacetic acid derivatives | BSAF AG (DE) | 2000-11-01 | — | — | CN | disclosed |
| US-4065620-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | HSP90AA1 847/4885TSHR 2965/4885ALDH1A1 4170/4885 |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | HSP90AA1 1381/4885TSHR 3997/4885ALDH1A1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.